Skip to main content
Publications
Hamadani M, Spira AI, Zhou X , Liao L, Chen L, Radford J, Ai WZ, Solh MM, Ardeshna KM, Hess BT, Caimi PF, Stathis A, Carlo Stella C, Alderuccio JP, Kahl BS, Wang Y, Qin YG, Xu ZC, Zinzani PL. Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial . Blood Adv. 2024 Jan;9(1):93-8. doi: 10.1182/bloodadvances.2023010636
Salles G, Schuster SJ, Dreyling M, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith SM, Jimenez-Ubieto A, Davis KL , Anjos C, Chu J, Zhang J, Lobetti Bodoni C, Thieblemont C, Fowler NH, Dickinson M, Martinez-Lopez J, Wang Y, Link BK. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma . Blood Adv. 2022 Nov 22;6(22):5835-43. doi: 10.1182/bloodadvances.2022008150
Li Y, Misumi I, Shiota T, Sun L, Lenarcic EM, Kim H, Shirasaki T, Hertel-Wulff A, Tibbs T , Mitchell JE, McKnight KL, Cameron CE, Moorman NJ, McGivern DR, Cullen JM, Whitmire JK, Lemon SM. The ZCCHC14/TENT4 complex is required for hepatitis A virus RNA synthesis . Proc Natl Acad Sci U S A. 2022 Jul 12;119(28):e22045111. doi: 10.1073/pnas.2204511119.
Cheol Lee J, Hung JY, Kim YC, Chang GC, Soo Yoo S, Yang SH, Davis KL , Nagar SP , Taylor A, Yong Lee S, Shih JY. Real-world treatment patterns in patients with EGFR mutation-positive NSCLC receiving a first line, first- or second-generation EGFR tyrosine kinase inhibitor in South Korea and Taiwan . Asian Pac J Cancer Bio. 2021 May 20;6(2). doi: 10.31557/APJCB.2021.6.2.123-132
Dadvand P, Nieuwenhuijsen MJ, Esnaola M, Forns J , Basagana X, Alvarez-Pedrerol M, Rivas I, Lopez-Vicente M, De Castro Pascual M, Su J, Jerrett M, Querol X, Sunyer J. Green spaces and cognitive development in primary schoolchildren . Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):7937-42. doi: 10.1073/pnas.1503402112